BUZZ-Aeterna Zentaris Inc: Committee recommends late-stage trial continue

Tue Oct 13, 2015 8:32am EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Canadian drug developer's U.S.-listed shares up 15 pct at 9 cents

** Aeterna says an independent data and safety monitoring committee recommended it continue testing its endometrial cancer drug in a late-stage study

** The drug, zoptarelin doxorubicin, is being tested in women with advanced, recurrent or metastatic endometrial cancer; drug is also being evaluated for use in ovarian and prostate cancer

** If all goes well, the drug could become the first FDA-approved therapy for the condition, company says

** There will be about 50,000 new cases of endometrial cancer in the U.S. in 2015, about 20 pct of which will recur, the American Cancer Society estimates

** Up to Monday's close, U.S.-listed stock had risen about 87 pct this year